Summary of Ionis Pharmaceuticals FY Conference Call Company Overview - **Company**: Ionis Pharmaceuticals (NasdaqGS:IONS) - **Focus**: Genetic medicines targeting RNA for clinically meaningful diseases with high unmet needs - **Year Ahead**: 2026 is expected to be a transformational year with significant momentum from 2025 [3][4] Key Product Launches and Financial Performance - **TRYNGOLZA**: - First FDA-approved medicine for familial chylomicronemia syndrome (FCS) - Generated $108 million in total revenue in 2025, exceeding estimates [4] - Strong quarter-over-quarter growth and positive patient feedback [9] - **DAWNZERA**: - Approved for hereditary angioedema, also showing a good start post-launch [4] - **Severe Hypertriglyceridemia (SHTG)**: - Upcoming launch in July 2026, with priority review from the FDA [6] - Expected to significantly increase patient population from 3,000 (FCS) to 3 million (SHTG) [11] - Anticipated peak product sales of over $2 billion in the U.S. [17] Clinical Developments and Pipeline - **Alexander Disease**: - Positive Phase 3 data expected to lead to approval and launch in fall 2026 [7] - **Partnered Pipeline**: - Five Phase 3 readouts expected in 2026, including studies for ATTR cardiomyopathy and Lp(a) cardiovascular disease [7] - **ATTR Cardiomyopathy**: - Estimated 500,000 patients in the U.S. with high unmet needs [25] - Potential peak product sales of over $5 billion for eplontersen, a silencer drug [28] - **Lp(a) Cardiovascular Disease**: - Phase 3 study (HORIZON) expected to read out in the second half of 2026, aiming for significant reductions in Lp(a) levels [34][35] Pricing Strategy and Market Considerations - **Pricing for SHTG**: - Initial pricing strategy to transition from a rare disease price to a specialty price, with a focus on maximizing patient access [11][12] - Estimated net price range of $10,000-$20,000 for SHTG [12] - **Market Dynamics**: - Facing pricing pressure from competitors, but managing effectively [10][20] - Anticipated revenue dip initially due to pricing adjustments, with expected recovery in the second half of 2026 [22][18] Research and Development Insights - **Tau Program with Biogen**: - Focus on tau targeting for neurodegenerative diseases, with positive Phase 1, 2 data indicating potential cognitive improvements [39] - **Angelman's Syndrome**: - Rare disease with no effective treatments; Ionis is optimistic about its drug ION582 based on strong early clinical data [40][42] Conclusion - Ionis Pharmaceuticals is positioned for significant growth in 2026 with multiple product launches and a robust pipeline. The company is navigating market challenges while focusing on maximizing patient access and addressing high unmet medical needs across its therapeutic areas [43][44]

Summary of Ionis Pharmaceuticals FY Conference Call Company Overview - **Company**: Ionis Pharmaceuticals (NasdaqGS:IONS) - **Event**: 46th Annual TD Cowen Healthcare Conference - **Date**: March 02, 2026 Key Points Industry and Company Transformation - 2026 is anticipated to be a transformative year for Ionis, building on the momentum from 2025, which was also a significant year for the company [5][6] - Ionis transitioned from a research-focused entity to a fully integrated commercial biotechnology company, achieving two independent product launches: TRYNGOLZA for familial chylomicronemia syndrome (FCS) and DAWNZERA for hereditary angioedema (HAE) prophylaxis [5][6] Product Launches and Pipeline - **TRYNGOLZA**: - First FDA-approved medicine for FCS, launched successfully in 2025 [5] - Expected to expand into severe hypertriglyceridemia (sHTG) with a PDUFA date of June 30, 2026, representing a multibillion-dollar market opportunity [6][12] - **DAWNZERA**: - Launched in September 2025, with $8 million in revenue reported for the year [21] - Primarily attracting switch patients from existing therapies, particularly TAKHZYRO [25] Clinical Trials and Data Readouts - Anticipation of five phase 3 readouts from partnered pipelines in 2026, including successful results for bepirovirsen for chronic HBV [7] - New phase 3 trials planned for salanersen (spinal muscular atrophy) and sapablursen (polycythemia) [8] Financial Guidance and Revenue Expectations - Initial revenue guidance for TRYNGOLZA was $820-$825 million, which is expected to be revised upwards due to priority review status for sHTG [9][10] - Ionis aims to reduce net operating loss and provide detailed product-level revenue guidance in the upcoming Q1 earnings call [10] Pricing Strategy - Pricing for TRYNGOLZA is expected to be in the range of $10,000-$20,000 net price, with considerations for competitive pricing against a new entrant in the FCS space [17] - The company is focused on maximizing patient access while preserving value for stakeholders [13][17] Clinical Data and Safety Observations - Positive phase 3 data for triglyceride lowering in sHTG, showing over 70% reduction in triglycerides and 85% reduction in acute pancreatitis attacks [12][19] - Observations of a small increase in hepatic fat during treatment, which is not considered a toxicity and is expected to normalize over time [20] Future Studies and Market Potential - The CARDIO-TTRansform study is set to provide significant data on ATTR cardiomyopathy, with peak market sales for WAINUA expected to exceed $5 billion [36] - The study aims to demonstrate the benefits of combining silencer and stabilizer therapies, which could enhance treatment outcomes for patients [37][38] Angelman Syndrome Study - The phase 3 study for ION582 will focus on an 80-milligram dose, as long-term data indicated greater efficacy without safety concerns [46][47] - Enrollment is progressing well, with expectations to complete this year and report data next year [47][48] Additional Insights - The company is strategically managing the launch of DAWNZERA with a free drug program to facilitate patient access while navigating payer negotiations [23][24] - Ionis is committed to providing comprehensive data sets from ongoing studies, which will support its market positioning and product efficacy claims [40][41]

Core Insights - Ionis Pharmaceuticals is entering a pivotal phase in 2025, transitioning into a fully integrated commercial-stage biotechnology company with strong initial launches of TRYNGOLZA and DAWNZERA [1][4] Commercial Performance - TRYNGOLZA generated $108 million in its first year, with a 56% quarter-over-quarter revenue increase, leading to raised peak sales expectations for the combined FCS/sHTG opportunity to over $2 billion [5][10] - DAWNZERA is positioned as the first RNA-targeted medicine for hereditary angioedema (HAE) prevention, resonating well with physicians and patients [11] Product Launch and Pipeline - The FDA accepted Ionis' supplemental NDA for olezarsen in severe hypertriglyceridemia (sHTG) with a priority review and a PDUFA date of June 30, positioning the company for a launch at the end of June or early July [4][6] - Ionis anticipates three product approvals and launches in 2026, including olezarsen for sHTG, zilganersen for Alexander disease, and bepirovirsen for chronic hepatitis B [5][8] Market Opportunity - The sHTG market is significant, affecting over 3 million people in the U.S., with an estimated 1 million high-risk patients eligible for olezarsen [8] - The initial launch focus for sHTG will target high-risk patients with triglycerides above 500 and those above 880, based on feedback from medical specialists [12] Financial Guidance - The priority review for olezarsen is expected to accelerate market entry by four months, leading to improved financial guidance, which will be updated during the end-of-first-quarter earnings call [13] Neurology Pipeline - Ionis is advancing its neurology franchise with the upcoming launch of zilganersen for Alexander disease, supported by positive phase III data [14] - The phase III program for obinutersen in Angelman syndrome is ongoing, with enrollment expected to complete this year [15]

Core Insights - Ionis Pharmaceuticals, Inc. reported total revenue of $944 million for the fiscal year 2025, a significant increase from $705 million in the previous year, driven by commercial success and substantial R&D revenue [1] - The company received a $280 million upfront payment for the global license of sapablursen to Ono Pharmaceutical Co., Ltd. in Q2 2025 [1] - Operating expenses for the full year were in line with expectations, increasing year over year due to investments in commercialization efforts for drugs such as TRYNGOLZA, DAWNZERA, and WAINUA [2] Financial Performance - Total revenue for Q4 2025 was $203 million, down from $227 million in the same period the previous year [1] - Needham raised the price target for Ionis Pharmaceuticals to $103 from $90, maintaining a Buy rating, indicating an optimistic outlook for the company's 2026 revenue [2] Company Overview - Ionis Pharmaceuticals specializes in developing and commercializing human therapeutic drugs using antisense technology, operating through the Ionis Core segment which generates a pipeline of drugs via a novel drug discovery platform [3]

Summary of Ionis Pharmaceuticals FY Conference Call Company Overview - **Company**: Ionis Pharmaceuticals (NasdaqGS:IONS) - **Event**: FY Conference Call on February 26, 2026 - **Key Speaker**: Brett Monia, CEO Core Industry and Company Insights - **FDA Acceptance**: The FDA accepted the supplemental NDA for olezarsen to treat severe hypertriglyceridemia (sHTG) with priority review status, setting a PDUFA date of June 30, 2026, which positions the company for a launch in late June or early July [2][3] - **Transformational Year**: 2025 was described as a pivotal year for Ionis, marking its transition to a fully integrated commercial-stage biotechnology company with successful independent launches of TRYNGOLZA for familial chylomicronemia syndrome (FCS) and DAWNZERA for hereditary angioedema (HAE) [3][4] - **Revenue Growth**: The company aims to achieve cash flow break-even by 2028, with expectations of accelerating revenue growth driven by its innovative pipeline [4][5] Product Pipeline and Launch Strategy - **Pipeline Success**: Ionis has had six positive Phase 3 readouts and four approved medicines in the last two and a half years, with 11 medicines in late-stage development [6][7] - **Upcoming Launches**: Expected product approvals and launches in 2026 include: - Olezarsen for sHTG - Zilganersen for Alexander disease - Bepirovirsen for chronic HBV [7][8] - **Market Focus**: Initial launch strategy for sHTG will prioritize patients with a history of acute pancreatitis and those with triglyceride levels above 880, as these patients are at the highest risk [29][30] Financial Projections - **Revenue Guidance**: The acceptance of the priority review for olezarsen is expected to improve revenue guidance, with updates to be provided in the Q1 earnings call [32] - **Peak Product Revenue**: The company anticipates over $4 billion in potential annual peak product revenue from its own medicines, with an additional $2 billion from partnered medicines, totaling over $6 billion in revenue [20][21] Neurology Portfolio - **Zilganersen Launch**: Zilganersen is positioned as Ionis' first independent launch in neurology, with positive Phase 3 data reported and an NDA submitted [19][36] - **Future Developments**: The company is also working on the Angelman syndrome program, which has received Breakthrough Therapy designation and is expected to complete enrollment in its Phase III study this year [20][39] Competitive Landscape and Innovation - **DAWNZERA's Competitive Edge**: DAWNZERA is noted for its compelling product profile, offering better efficacy, tolerability, and convenience compared to existing treatments for HAE [11][12] - **Follow-On Programs**: Ionis is exploring follow-on programs for its existing products to enhance dosing convenience and efficacy [33][34] Conclusion - **Outlook**: Ionis Pharmaceuticals is positioned for a transformative year in 2026, with multiple product launches and a strong pipeline that addresses significant unmet medical needs in cardiometabolic and neurological diseases [21][42]

Core Insights - Ionis Pharmaceuticals reported an EPS of -$1.41, missing consensus estimates of around -$1.23, but exceeded revenue expectations with $203 million in total revenue [1][3] - The company has shown a pattern of revenue beats in recent quarters despite a year-over-year decline in Q4 total revenue [4] Financial Performance - Ionis reported a total revenue of $203 million for Q4 2025, which is an ~11% decline from $227 million in Q4 2024, but surpassed the Zacks Consensus Estimate by ~30% [3][4] - Commercial revenue grew approximately 64% to ~$141 million in Q4, driven by products like TRYNGOLZA, offsetting declines in royalties and R&D revenue [4] - The current ratio stands at approximately 2.79, indicating good short-term financial health despite ongoing unprofitability [2][5] Valuation Metrics - Ionis has a negative price-to-earnings (P/E) ratio of approximately -50, indicating current unprofitability [5] - The price-to-sales ratio is about 13, suggesting investors are willing to pay a premium for revenue amid pipeline expectations [5] - The enterprise value to sales ratio is also approximately 13, reflecting the company's valuation relative to revenue [5] Future Outlook - Ionis is focused on discovering and developing RNA-targeted therapeutics, with multiple independent launches planned for 2026 [2] - CEO Brett P. Monia emphasized the potential for continued success in 2026, highlighting upcoming launches such as olezarsen for sHTG and zilganersen for AxD [4]

Core Insights - The company has successfully transitioned into a fully integrated commercial-stage entity following the independent launches of TRYNGOLZA and DAWNZERA [1] - TRYNGOLZA's performance was attributed to its compelling clinical profile and strong execution, achieving $108 million in full-year revenue [1] - Breakthrough Phase III results for olezarsen in severe hypertriglyceridemia showed an unprecedented 85% reduction in acute pancreatitis events [1] - Positive Phase III data for zilganersen has strengthened the company's strategic positioning in neurology, marking it as the first therapy to demonstrate disease-modifying benefits in Alexander disease [1] - The company experienced a revenue growth of 34% year-over-year, supported by a diversified model that includes recurring income from marketed medicines and financial accelerators from R&D collaborations [1] - Disciplined investment strategies have allowed the company to exceed financial guidance while expanding its commercial field organization to 200 members [1]

Core Insights - Ionis Pharmaceuticals has successfully executed its first two independent commercial launches, DAWNZERA and TRYNGOLZA, marking a significant year for the company [3] Product Launches - DAWNZERA, approved in August as a prophylactic treatment for hereditary angioedema (HAE), is the first RNA-targeted medicine for HAE, with a peak sales potential exceeding $500 million [1] - TRYNGOLZA, the first FDA-approved treatment for familial chylomicronemia syndrome (FCS), generated fourth-quarter net product sales of $50 million, a 56% increase sequentially, and full-year revenue of $108 million [2][6] Financial Performance - Ionis reported 2025 revenue of $944 million, a 34% year-over-year increase, with 46% from commercial products and 54% from R&D collaborations [12] - The company provided 2026 revenue guidance of $800 million to $825 million, reflecting a one-time $280 million license fee in 2025, indicating approximately 20% underlying growth [4][14] Pipeline Developments - Olezarsen for severe hypertriglyceridemia (sHTG) showed up to a 72% triglyceride reduction and an 85% reduction in acute pancreatitis events, with a supplemental NDA submitted and priority review requested [5][8] - Zilganersen for Alexander disease is anticipated to receive approval in the second half of 2026, with peak revenue guidance exceeding $100 million [9] Commercial Strategy - The company emphasized strong early adoption for DAWNZERA, with a 100% conversion to paid therapy from the free trial program [1] - Management noted that approximately 75% of TRYNGOLZA prescriptions came from specialists, indicating a targeted approach to market penetration [2] Future Outlook - Ionis aims for cash-flow breakeven by 2028, with a projected non-GAAP operating loss of $500 million to $550 million for 2026 [20][21] - The company expects a meaningful decline in TRYNGOLZA revenue during 2026 ahead of the sHTG launch, followed by growth if approval occurs [16]

Financial Data and Key Metrics Changes - In 2025, Ionis Pharmaceuticals generated $944 million in revenue, representing a 34% increase year-over-year [30] - Revenue from commercial products was $436 million (46% of total revenue), while R&D collaborations contributed $508 million (54% of total revenue) [30] - Royalty revenues increased by 11% to $285 million, driven by contributions from Spinraza and Waylivra [32] Business Line Data and Key Metrics Changes - TRYNGOLZA generated $108 million in product sales in 2025, with a 56% increase in Q4 revenues compared to Q3 [31][19] - DAWNZERA achieved $8 million in product sales during its initial months of launch [31] - Olezarsen is projected to exceed $2 billion in peak annual sales, reflecting strong prescriber demand and positive Phase 3 data [24][66] Market Data and Key Metrics Changes - The U.S. market for severe hypertriglyceridemia (sHTG) is significant, with over 1 million individuals affected [22] - The payer mix for TRYNGOLZA is approximately 60% commercial and 40% government, with strong access for both clinically diagnosed and genetically confirmed patients [21] Company Strategy and Development Direction - Ionis aims to achieve cash flow breakeven by 2028, with a focus on launching multiple medicines and advancing its high-value pipeline [39] - The company is preparing for the anticipated launch of Olezarsen for sHTG and expects to leverage its strong relationships with the neurology community for zilganersen [28][29] - Ionis is committed to maximizing the potential of its marketed medicines while preparing for additional launches in 2026 [29] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver transformational medicines and create shareholder value, citing strong commercial momentum and a robust pipeline [42] - The anticipated approval of Olezarsen is expected to drive significant revenue growth, with management actively engaging with payers to ensure broad access [48][49] Other Important Information - The company has a diversified revenue stream that mitigates risk and enhances financial flexibility [30] - Ionis is on track for three additional launches in 2026, including its first in a broad patient population [42] Q&A Session Summary Question: Guidance on sHTG sales and pricing dynamics - Management clarified that current guidance assumes standard review for Olezarsen, with sales from TRYNGOLZA expected until the sHTG launch [46][47] Question: Reimbursement in FCS and pricing dynamics - Management noted strong patient demand for TRYNGOLZA and ongoing discussions with payers to maximize access while balancing pricing [56][57] Question: Peak sales expectations for Olezarsen - Management increased confidence in the $2 billion peak sales estimate based on strong product profile and prescriber demand research [63][66] Question: FDA interactions regarding sHTG filing - Management indicated that interactions with the FDA have been positive, and they believe Olezarsen deserves priority review [70][72] Question: European sites for Angelman syndrome program - Management confirmed plans to open European sites pending approval from regulators [81][82]

Financial Data and Key Metrics Changes - Ionis Pharmaceuticals reported a revenue increase of 34% year-over-year, reaching $944 million in 2025, with commercial products contributing $436 million and R&D collaborations $508 million [30][31] - The company exceeded its financial guidance across all metrics, driven by strong execution and disciplined financial management [30][32] - Non-GAAP operating expenses increased modestly year-over-year, primarily due to investments related to the U.S. launch of TRYNGOLZA and DAWNZERA [32][39] Business Line Data and Key Metrics Changes - TRYNGOLZA generated $108 million in product sales in 2025, with a 56% increase in Q4 revenues compared to Q3 [19][31] - DAWNZERA achieved $8 million in product sales from its initial months of launch, with strong participation in a free trial program leading to 100% conversion to paid therapy [31][36] - Olezarsen is projected to exceed $2 billion in peak annual revenue, reflecting strong prescriber demand and positive Phase 3 data [24][66] Market Data and Key Metrics Changes - The payer mix for TRYNGOLZA is approximately 60% commercial and 40% government, with broad access for both clinically diagnosed and genetically confirmed patients [22][31] - The company anticipates a meaningful decline in TRYNGOLZA revenues throughout 2026 ahead of the sHTG launch, followed by accelerating growth post-approval [35][48] Company Strategy and Development Direction - Ionis is focused on maximizing the potential of its marketed medicines while preparing for multiple upcoming launches, including Olezarsen for sHTG and Zilganersen for Alexander disease [29][39] - The company aims to achieve cash flow breakeven by 2028, supported by a diversified revenue stream and disciplined investment strategy [30][39] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to deliver transformational medicines and create shareholder value, citing strong commercial momentum and an advancing pipeline [41][43] - The company is actively engaging with payers to ensure broad access for its products while balancing long-term value realization [48][56] Other Important Information - Ionis received breakthrough therapy designation from the FDA for Olezarsen, which is currently under review [17][72] - The company is preparing for the anticipated U.S. approval of high-dose Spinraza, with a PDUFA date set for April 3rd [18] Q&A Session Summary Question: Guidance on sHTG sales and pricing dynamics - Management clarified that current guidance assumes standard review for Olezarsen, with sales from the sHTG patient population expected in Q4 [46][47] - Discussions with payers are ongoing to ensure broad access for TRYNGOLZA prior to the sHTG launch, with a meaningful decline in revenues anticipated until then [48][49] Question: Reimbursement in FCS and pricing dynamics - The company reported no significant impact from competitors on TRYNGOLZA demand, with strong patient access maintained [56][59] Question: Peak revenue for Olezarsen - Management expressed increased confidence in the $2 billion peak revenue estimate for Olezarsen, driven by strong demand trends and positive Phase 3 data [63][66] Question: FDA interactions regarding sHTG filing - Management indicated that interactions with the FDA have been positive, and they believe Olezarsen deserves priority review designation [72][73] Question: European sites for Angelman syndrome program - The company is awaiting approval to open European sites for the Angelman syndrome program and plans to do so once approval is received [81][82]